Liberum Capital Reiterates GBX 94.00 Target Price On Non-standard Finance Plc (LON:NSF), Reiterates Buy Rating; LHC Group (LHCG) Sentiment Is 1.15

LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company has market cap of $1.17 billion. The firm operates through four divisions: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. It has a 23.02 P/E ratio. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.

In a report issued to clients on today, Liberum Capital maintained their Buy rating on Non-standard Finance Plc (LON:NSF)‘s stock. The target gives a potential upside of 36.63% from company’s last price.

Oberweis Asset Management Inc holds 1.77% of its portfolio in LHC Group, Inc. for 89,520 shares. First Light Asset Management Llc owns 64,672 shares or 1.45% of their US portfolio. Moreover, Walthausen & Co. Llc has 1.24% invested in the company for 187,890 shares. The Connecticut-based Sivik Global Healthcare Llc has invested 1.23% in the stock. Dalton Greiner Hartman Maher & Co, a New York-based fund reported 244,295 shares.

The stock increased 0.55% or $0.35 during the last trading session, reaching $64.22. About 242,991 shares traded. LHC Group, Inc. (LHCG) has risen 42.98% since March 13, 2017 and is uptrending. It has outperformed by 26.28% the S&P500.

Non-Standard Finance plc engages in the consumer credit business in the United Kingdom. The company has market cap of 217.10 million GBP. It provides unsecured personal loans in the home credit market; branch unsecured consumer loans; and guaranteed loans. It currently has negative earnings.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: